SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 101 filers reported holding SPERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $6,806,000 | +72.6% | 3,403,210 | -36.0% | 2.45% | +82.2% |
| Q2 2022 | $3,943,000 | -91.4% | 5,321,231 | +0.8% | 1.35% | -80.1% |
| Q1 2022 | $45,949,000 | -42.2% | 5,281,504 | +6.4% | 6.75% | -25.1% |
| Q4 2021 | $79,477,000 | -5.4% | 4,964,181 | +8.8% | 9.01% | -40.9% |
| Q3 2021 | $84,017,000 | +57.2% | 4,563,688 | +19.2% | 15.26% | +9.9% |
| Q2 2021 | $53,456,000 | -5.2% | 3,829,209 | 0.0% | 13.89% | +36.4% |
| Q1 2021 | $56,366,000 | -26.1% | 3,829,209 | -2.6% | 10.19% | -35.7% |
| Q4 2020 | $76,246,000 | +51.9% | 3,932,209 | -12.6% | 15.85% | +198.2% |
| Q3 2020 | $50,188,000 | +90.9% | 4,497,142 | +131.4% | 5.31% | +0.2% |
| Q2 2020 | $26,290,000 | +79.0% | 1,943,081 | +6.9% | 5.30% | -7.4% |
| Q1 2020 | $14,691,000 | +32.4% | 1,818,140 | +57.5% | 5.73% | +37.3% |
| Q4 2019 | $11,099,000 | -9.3% | 1,154,356 | 0.0% | 4.17% | -51.6% |
| Q3 2019 | $12,236,000 | -7.9% | 1,154,356 | 0.0% | 8.62% | +86.8% |
| Q2 2019 | $13,287,000 | -1.6% | 1,154,356 | +9.5% | 4.61% | -22.9% |
| Q1 2019 | $13,506,000 | +112.8% | 1,054,356 | +2.2% | 5.98% | +94.7% |
| Q4 2018 | $6,346,000 | – | 1,031,947 | – | 3.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |